Showing 4821-4830 of 9153 results for "".
- National Academy of Dermatology Nurse Practitioners Inaugural Conference in Mayhttps://practicaldermatology.com/news/20120224-national_academy_of_dermatology_nurse_practitioners__inaugural_conference_in_may/2459865/The inaugural conference of the National Academy of Dermatology Nurse Practitioners will be held May 2-5, 2012 in Clearwater Beach, FL at the Sheraton Sand Key Resort. Designed for all nurse practitioners regardless of experience or practice seting, the program covers both medical and aesthetic derm
- New Rosacea Gel Coming Soonhttps://practicaldermatology.com/news/20120202-new_rosacea_gel_coming_soon/2459871/SkinCeuticals will soon unveil its Redness Neutralizer, a lightweight gel cream that prevents redness by targeting environmental triggers of inflammation leading to the onset of rosacea. Formulated wi
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://practicaldermatology.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- Dr. Peter Lio Named Fall Clinical Educator of the Yearhttps://practicaldermatology.com/news/dr-peter-lio-named-fall-clinical-educator-of-the-year/2484092/Peter Lio, MD, was presented with the Educator of the Year Award at the 2025 Fall Clinical Dermatology Conference. Dr. Lio is founding director of the Chicago Integrative Eczema Center and a member of Practical Dermatology’s Editorial Board. Dr. Lio spoke at the Fall Clinical Meetin
- Bullous Pemphigoid: The Time to Treat Is Now, Fall Clinical Speakers Sayhttps://practicaldermatology.com/news/bullous-pemphigoid-the-time-to-treat-is-now-fall-clinical-speakers-say/2484090/Earlier recognition of bullous pemphigoid (BP) is critical but safer, targeted treatment options are emerging for this aging and medically fragile patient population, according to a presentation from Donna Culton, MD, PhD, and Prince Adotama, MD, at the 2025 Fall Clinical Dermatology Conference.<